Secarna Pharmaceuticals and Protalix Biotherapeutics Partner on Rare Disease Therapies

Secarna Pharmaceuticals and Protalix Biotherapeutics have announced a collaboration and option agreement to develop pharmaceutical candidates for rare renal conditions. This partnership merges Protalix's expertise in rare disease therapeutics with Secarna's AI-powered OligoCreator® platform.

Protalix gains an exclusive option to license compounds from the research for possible clinical development and commercialization. The aim is to advance programs from the preclinical stage to clinical trials. Secarna will design antisense oligonucleotide candidates targeting biological roles in rare renal conditions.

This agreement signifies Protalix's first foray into rare kidney disease leveraging RNA technologies, expanding its focus in rare disease therapeutics. Both companies seek to deliver novel treatments for severe kidney disorders, addressing significant unmet medical needs in the sector.